Published in World J Biol Psychiatry on January 01, 2008
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement (2014) 1.28
Beta-amyloid deposition and the aging brain. Neuropsychol Rev (2009) 1.25
Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics (2008) 1.13
Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions. Alzheimers Res Ther (2010) 0.97
Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med (2010) 0.93
Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiol Aging (2010) 0.89
Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. Neuropsychology (2014) 0.87
Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. Front Aging Neurosci (2014) 0.86
APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. BMC Neurol (2015) 0.86
Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers. Dement Geriatr Cogn Dis Extra (2013) 0.86
CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy. Acta Neuropathol (2010) 0.86
Using biomarkers to improve detection of Alzheimer's disease. Neurodegener Dis Manag (2011) 0.84
Comparative analysis of autophagy and tauopathy related markers in cerebral ischemia and Alzheimer's disease animal models. Front Aging Neurosci (2015) 0.84
To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci (2009) 0.83
Plasma and cerebrospinal fluid amyloid-β levels in late-life depression: A systematic review and meta-analysis. J Psychiatr Res (2015) 0.83
Combining cognitive screening tests for the evaluation of mild cognitive impairment in the elderly. Clinics (Sao Paulo) (2009) 0.81
Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid. AAPS J (2012) 0.81
Cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and cognition in aging and Alzheimer disease. J Neuropathol Exp Neurol (2013) 0.81
A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer's disease. SAGE Open Med (2015) 0.77
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croat Med J (2014) 0.77
Comparison of visual evoked potentials and retinal nerve fiber layer thickness in Alzheimer's disease. Front Neurol (2013) 0.77
Improving CSF Biomarkers' Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer's Disease by Considering Different Confounding Factors: A Meta-Analysis. Front Aging Neurosci (2014) 0.77
Nuclear Tau and Its Potential Role in Alzheimer's Disease. Biomolecules (2016) 0.76
Gavage of D-Ribose induces Aβ-like deposits, Tau hyperphosphorylation as well as memory loss and anxiety-like behavior in mice. Oncotarget (2015) 0.76
Diffusion tensor imaging reveals visual pathway damage in patients with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis (2015) 0.76
Allocentric Spatial Memory Testing Predicts Conversion from Mild Cognitive Impairment to Dementia: An Initial Proof-of-Concept Study. Front Neurol (2016) 0.75
Genomic and Proteomic Biomarker Discovery in Neurological Disease. Biomark Insights (2008) 0.75
Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review. Neuropsychol Rev (2015) 0.75
Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts. Front Aging Neurosci (2017) 0.75
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Alzheimers Res Ther (2017) 0.75
Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. Eur Arch Psychiatry Clin Neurosci (2008) 1.03
Mild cognitive impairment: cognitive screening or neuropsychological assessment? Rev Bras Psiquiatr (2008) 0.97
White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: a critical review of MRI studies. Expert Rev Neurother (2013) 0.96
Profiles of functional deficits in mild cognitive impairment and dementia: benefits from objective measurement. J Int Neuropsychol Soc (2010) 0.96
Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat (2013) 0.95
Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. J Psychiatr Res (2010) 0.91
Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. World J Biol Psychiatry (2010) 0.91
Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis (2010) 0.88
Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels. Curr Alzheimer Res (2014) 0.87
Diagnosis of mild cognitive impairment revisited after one year. Preliminary results of a prospective study. Dement Geriatr Cogn Disord (2009) 0.86
Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients. Am J Geriatr Psychiatry (2010) 0.85
Optimizing the CAMCOG test in the screening for mild cognitive impairment and incipient dementia: saving time with relevant domains. Int J Geriatr Psychiatry (2011) 0.84
Verbal fluency in the detection of mild cognitive impairment and Alzheimer's disease among Brazilian Portuguese speakers: the influence of education. Int Psychogeriatr (2009) 0.84
To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci (2009) 0.83
Cross-cultural adaptation, reliability and validity of the DAFS-R in a sample of Brazilian older adults. Arch Clin Neuropsychol (2010) 0.83
Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment? World J Biol Psychiatry (2011) 0.81
Language impairment in euthymic, elderly patients with bipolar disorder but no dementia. Int Psychogeriatr (2008) 0.81
Combining functional scales and cognitive tests in screening for mild cognitive impairment at a university-based memory clinic in Brazil. Rev Bras Psiquiatr (2008) 0.80
Psychometric characteristics of the Rivermead Behavioural Memory Test (RBMT) as an early detection instrument for dementia and mild cognitive impairment in Brazil. Int Psychogeriatr (2010) 0.78
Cognitive-linguistic deficits in euthymic elderly patients with bipolar disorder. J Affect Disord (2013) 0.77
Functional mobility in a divided attention task in older adults with cognitive impairment. J Mot Behav (2015) 0.77
Reduced activities of phospholipases A2 in platelets of drug-naïve bipolar disorder patients. Bipolar Disord (2014) 0.77
Fear of falling and falls in older adults with mild cognitive impairment and Alzheimer's disease. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2014) 0.77
Higher proportion of inactive Gsk3β in platelets of elderly patients with bipolar disorder: an effect of treatment? Rev Bras Psiquiatr (2013) 0.76
The Brazilian version of the Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity in dementia. Int Psychogeriatr (2013) 0.76
Formal Thought Disorder and language impairment in schizophrenia. Arq Neuropsiquiatr (2012) 0.75
Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer's Disease Platelets. J Alzheimers Dis (2016) 0.75